Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lumos Diagnostics HoldingsASX:LDX 26 Cash-to-Debt is 2.60 as of Jun. 2026, which is 225% above its 10-year median of 0.80. GuruFocus rates ASX:LDX with a GF Score™ of 26/100 and a GF Value™ of A$0.03 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 842 Medical Devices & Instruments companies, Lumos Diagnostics Holdings ranks better than 57.36% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Lumos Diagnostics Holdings's cash to debt ratio for the quarter that ended in Jun. 2026 was 2.60.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Lumos Diagnostics Holdingscould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Lumos Diagnostics Holdings's Cash-to-Debt or its related term are showing as below:
ASX:LDX'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.28 Med: 0.8 Max: 2.6
Current: 2.6
During the past 9 years, Lumos Diagnostics Holdings's highest Cash to Debt Ratio was 2.60. The lowest was 0.28. And the median was 0.80.
ASX:LDX's Cash-to-Debt is ranked better than 57.36% of 842
companies
in the Medical Devices & Instruments industry
Industry Median: 1.635
vs ASX:LDX: 2.60
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Lumos Diagnostics Holdings Cash-to-Debt Related Terms
Lumos Diagnostics Holdings Cash-to-Debt Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Medical Devices subindustry, Lumos Diagnostics Holdings's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lumos Diagnostics Holdings Cash-to-Debt vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Lumos Diagnostics Holdings's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Lumos Diagnostics Holdings's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lumos Diagnostics Holdings (ASX:LDX) has a Cash-to-Debt of 2.60 as of Jun. 2026. This is 225% above median its historical median of 0.80. Over the past decade, Lumos Diagnostics Holdings' Cash-to-Debt has ranged from 0.28 to 2.60. According to the industry distribution chart, Lumos Diagnostics Holdings ranks #359 out of 842 companies in the Medical Devices & Instruments industry, placing it in the top 42.6%.
Is Lumos Diagnostics Holdings' Cash-to-Debt too high?
Lumos Diagnostics Holdings' current Cash-to-Debt of 2.60 is 225% above median its 10-year median of 0.80. Over the past 10 years, this metric has ranged from a low of 0.28 to a high of 2.60. The Medical Devices & Instruments industry median Cash-to-Debt is 1.64. Lumos Diagnostics Holdings' value of 2.60 is 59% above this industry median. Based on the distribution chart, Lumos Diagnostics Holdings ranks #359 out of 842 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Lumos Diagnostics Holdings has a GF Score™ of 26/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lumos Diagnostics Holdings' Cash-to-Debt compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Lumos Diagnostics Holdings ranks #359 out of 842 companies for Cash-to-Debt. This puts Lumos Diagnostics Holdings in the upper half of its industry. The industry median Cash-to-Debt is 1.64. Lumos Diagnostics Holdings' value of 2.60 is 59% above this benchmark. Historically, Lumos Diagnostics Holdings' own Cash-to-Debt has ranged from 0.28 to 2.60 over the past decade. While the company's 10-year median is 0.80 vs. the industry median of 1.64, Lumos Diagnostics Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Devices & Instruments company?
The median Cash-to-Debt among Medical Devices & Instruments companies is 1.64, based on 842 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lumos Diagnostics Holdings's current Cash-to-Debt of 2.60 is 59% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Cash-to-Debt is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lumos Diagnostics Holdings's current Cash-to-Debt is 2.60, which is 225% above median its own 10-year median of 0.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lumos Diagnostics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Lumos Diagnostics Holdings (ASX:LDX) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.03, compared to a current price of A$0.11 — trading 266.7% above its estimated fair value. The current Cash-to-Debt is 2.60, which is 225% above median its 10-year median of 0.80 and 59% above the Medical Devices & Instruments industry median of 1.64. Lumos Diagnostics Holdings' overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Lumos Diagnostics Holdings (ASX:LDX), the current Cash-to-Debt is 2.60 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lumos Diagnostics Holdings (ASX:LDX) Overvalued in 2026?
Based on GuruFocus' analysis, Lumos Diagnostics Holdings stock appears to be overvalued.
The current stock price of A$0.11 is trading 266.7% above its estimated GF Value™ of A$0.03.
GuruFocus considers Lumos Diagnostics Holdings to be Significantly Overvalued.
Key valuation signals for ASX:LDX:
Cash-to-Debt: 2.60 (225% above median its 10-year median of 0.80)
GF Value™: A$0.03 vs. price of A$0.11 (266.7% above fair value)
Industry Position: 59% above the Medical Devices & Instruments median (#359 of 842)
No single metric tells the full story. See the ASX:LDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lumos Diagnostics Holdings Ltd is engaged in the development, manufacture, and distribution of point-of-care diagnostic (POC) tests and associated readers for analysis of POC diagnostic tests. The group is dedicated to providing contract research and development services, focusing on the innovation, development, manufacturing, and commercialization of point-of-care diagnostic solutions for both clinical and consumer applications. It generates maximum revenue from commercial services and solutions relating to POC diagnostic tests. The group has one operating segment, which is the provision of point-of-care diagnostics goods and services. The Company operates in two geographical regions, the United States and Australia and the majority of revenue is generated from the United States.
26GF Score
Get the complete analysis for ASX:LDX
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:LDX has been successfully added to your 
